It emphasized the challenging nature of finding the correct risk/benefit balance for the clinical setting given that it showed a 13.4% adjusted difference in the primary endpoint of hemostatic efficacy (hematoma expansion ≤ 35% at 12 h, increase in National Institutes of Health Stroke Scale/Score [NIHSS] of ≤7 points, and no receipt of rescue therapy between 3 and 12 h), as well as vastly superior median reduction in anti-FXa activity (94.5% versus 26.9%), but with a 4.6% absolute risk increase for thrombotic events, in particular ischemic stroke (6.5% versus 1.5%) (Table 1). This evidence concerns the gene F10 and ischemic stroke.